These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36438022)

  • 1. Prognostic and Immunological Roles of Cell Cycle Regulator CDCA5 in Human Solid Tumors.
    He J; Zhou X; Wang X; Zhang Q; Zhang L; Wang T; Zhu W; Liu P; Zhu M
    Int J Gen Med; 2022; 15():8257-8274. PubMed ID: 36438022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value and immunological role of FOXM1 in human solid tumors.
    Wei G; Yang X; Lu H; Zhang L; Wei Y; Li H; Zhu M; Zhou X
    Aging (Albany NY); 2022 Nov; 14(22):9128-9148. PubMed ID: 36435510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated Multi-omics Analyses Identify CDCA5 as a Novel Biomarker Associated with Alternative Splicing, Tumor Microenvironment, and Cell Proliferation in Colon Cancer Via Pan-cancer Analysis.
    Bao X; Leng X; Yu T; Zhu J; Zhao Y; Tenzindrogar ; Yang Z; Wu S; Sun Q
    J Cancer; 2024; 15(3):825-840. PubMed ID: 38213717
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical implication and immunological landscape analyses of ANLN in pan-cancer: A new target for cancer research.
    Zhang L; Wei Y; He Y; Wang X; Huang Z; Sun L; Chen J; Zhu Q; Zhou X
    Cancer Med; 2023 Feb; 12(4):4907-4920. PubMed ID: 36030492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of CDCA5 expression on the immune microenvironment and its potential utility as a biomarker for PD-L1/PD-1 inhibitors in lung adenocarcinoma.
    Koh YW; Hwang Y; Lee SK; Han JH; Haam S; Lee HW
    Transl Oncol; 2024 Aug; 46():102024. PubMed ID: 38838437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
    Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
    Front Oncol; 2022; 12():927988. PubMed ID: 35756681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing oncogene cell division cycle associated 5 induces apoptosis and G1 phase arrest of non-small cell lung cancer cells via p53-p21 signaling pathway.
    Shen W; Tong D; Chen J; Li H; Hu Z; Xu S; He S; Ge Z; Zhang J; Mao Q; Chen H; Xu G
    J Clin Lab Anal; 2022 May; 36(5):e24396. PubMed ID: 35373420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An integrated model of CDCA5 and FOXM1 expression combined with a residual disease that predicts prognosis in ovarian cancer patients.
    Zhang Q; Zhang R; Liu M; Wu H; Yang B
    Cell Mol Biol (Noisy-le-grand); 2023 Oct; 69(10):143-149. PubMed ID: 37953569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.
    Cao K; Ling X; Jiang X; Ma J; Zhu J
    Respir Res; 2022 Nov; 23(1):306. PubMed ID: 36357897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-Cancer Analysis Reveals the Multidimensional Expression and Prognostic and Immunologic Roles of
    Zhang S; Xiong H; Yang J; Yuan X
    Front Mol Biosci; 2021; 8():792154. PubMed ID: 35155565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma.
    Hou S; Chen X; Li M; Huang X; Liao H; Tian B
    Aging (Albany NY); 2020 Jul; 12(14):14542-14555. PubMed ID: 32694239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-Cancer Integrated Analysis of HSF2 Expression, Prognostic Value and Potential Implications for Cancer Immunity.
    Chen F; Fan Y; Liu X; Zhang J; Shang Y; Zhang B; Liu B; Hou J; Cao P; Tan K
    Front Mol Biosci; 2021; 8():789703. PubMed ID: 35087869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
    Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
    Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma.
    Li Z; Feng Y; Li P; Wang S; Liu X; Xia S
    Int J Gen Med; 2022; 15():3809-3826. PubMed ID: 35418778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis.
    Ye Y; Jiang H; Wu Y; Wang G; Huang Y; Sun W; Zhang M
    Front Mol Biosci; 2022; 9():1001225. PubMed ID: 36213111
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.